Small-molecule aggregates inhibit amyloid polymerization.

Many amyloid inhibitors resemble molecules that form chemical aggregates, which are known to inhibit many proteins. Eight known chemical aggregators inhibited amyloid formation of the yeast and mouse prion proteins Sup35 and recMoPrP in a manner characteristic of colloidal inhibition. Similarly, three known anti-amyloid molecules inhibited beta-lactamase in a detergent-dependent manner, which suggests that they too form colloidal aggregates. The colloids localized to preformed fibers and prevented new fiber formation in electron micrographs. They also blocked infection of yeast cells with Sup35 prions, which suggests that colloidal inhibition may be relevant in more biological milieus.

[1]  B. Shoichet,et al.  A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.

[2]  S. Lindquist,et al.  Self-Seeded Fibers Formed by Sup35, the Protein Determinant of [PSI +], a Heritable Prion-like Factor of S. cerevisiae , 1997, Cell.

[3]  H. True,et al.  A yeast prion provides a mechanism for genetic variation and phenotypic diversity , 2000, Nature.

[4]  Robert A. Grothe,et al.  Structure of the cross-β spine of amyloid-like fibrils , 2005, Nature.

[5]  B. Shoichet,et al.  High-throughput assays for promiscuous inhibitors , 2005, Nature chemical biology.

[6]  Roger Cooke,et al.  Conformational variations in an infectious protein determine prion strain differences , 2004, Nature.

[7]  F. Cohen,et al.  Pathway Complexity of Prion Protein Assembly into Amyloid* , 2002, The Journal of Biological Chemistry.

[8]  F. Cohen,et al.  High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. , 1996, Biochemistry.

[9]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[10]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[11]  F. Cohen,et al.  Separation of scrapie prion infectivity from PrP amyloid polymers. , 1996, Journal of molecular biology.

[12]  J. Weissman,et al.  Molecular Basis of a Yeast Prion Species Barrier , 2000, Cell.

[13]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[14]  J. Weissman,et al.  An efficient protein transformation protocol for introducing prions into yeast. , 2006, Methods in enzymology.

[15]  Christopher P Austin,et al.  A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.

[16]  Kristin E. D. Coan,et al.  Stability and equilibria of promiscuous aggregates in high protein milieus. , 2007, Molecular bioSystems.

[17]  Kate A. Stafford,et al.  Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Lehrach,et al.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Yankner,et al.  Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Shubo Han,et al.  The Flavonoid Baicalein Inhibits Fibrillation of α-Synuclein and Disaggregates Existing Fibrils* , 2004, Journal of Biological Chemistry.

[21]  K. Abid,et al.  The intriguing prion disorders , 2006, Cellular and Molecular Life Sciences CMLS.